Damora Therapeutics Inc
DMRA
NASDAQ
Biotechnology
$31.04
USD
+0.31 (+1.01%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.90B
Volume 260.7K
Revenue
—
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
—
TTM
— YoY
Operating Cash Flow
—
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2026 | Q2 2026 |
|---|---|---|
Revenue | 0.0 | 0.0 |
YoY Growth | — | — |
Cost of Revenue | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 |
Selling, General & Administrative | 7.0 | 9.5 |
Other Operating Expenses | 0.0 | 0.0 |
Total Operating Expenses | 30.8 | 35.0 |
Operating Income | -30.8 | -35.0 |
EBITDA | -30.8 | -35.0 |
Other Income / Expense | 0.0 | 0.0 |
Total Other Income / Expense | 3.1 | 4.1 |
Income Before Income Taxes | -27.7 | -30.9 |
Income Taxes | 0.0 | 0.3 |
Net Income | -27.8 | -31.2 |
Consolidated Net Income / Loss | -27.8 | -31.2 |
Net Income Attributable to Common Shareholders | -21.3 | -24.1 |
Basic EPS | -$0.62 | -$0.39 |
Diluted EPS | -$0.62 | -$0.39 |
Basic Shares Outstanding | 34.3M | 61.1M |
Diluted Shares Outstanding | 34.3M | 61.1M |